CDC Has Updated Artemether-Lumefantrine Dosing to 5 Days for Falciparum Malaria
Yes, the CDC has updated its recommendation to extend artemether-lumefantrine (AL) treatment from the standard 3-day (6-dose) regimen to a 5-day (10-dose) regimen for uncomplicated Plasmodium falciparum malaria in the United States 1.
Background on the Change
The standard FDA-approved dosing remains 3 days (6 doses total): 4 tablets at 0 and 8 hours on day 1, then twice daily for 2 more days 2. However, mounting evidence of treatment failures has prompted CDC to revise its guidance.
Why the Change Was Made
Between November 2022 and October 2025, CDC documented 47 P. falciparum treatment failures in travelers, with 40 (85%) occurring after AL treatment 1. Critically:
- 85% were late recrudescences occurring 1-8 weeks after initial treatment
- 62% presented with severe malaria upon recurrence
- All patients had traveled to Africa
- Meta-analysis showed treatment failure risk increased to 7% for data from 2018 or later compared to 4% before 2018 1
The primary mechanism appears to be inadequate lumefantrine exposure, particularly in higher body weight patients, rather than confirmed artemisinin resistance 3. Swiss guidelines had already recommended this extension based on similar observations 3.
The New CDC Recommendation
For uncomplicated P. falciparum malaria in the United States, use a 5-day (10-dose) AL regimen:
- Days 1-2: Standard dosing (4 tablets at 0 and 8 hours on day 1, then twice daily on day 2)
- Days 3-5: Continue twice daily dosing for 3 additional days
- Total: 10 doses over 5 days instead of 6 doses over 3 days
This extended regimen consistently achieves higher lumefantrine exposure and has been well tolerated in clinical use 1.
Important Caveats
When Standard 3-Day Dosing May Still Apply
The FDA label has not changed—the 3-day regimen remains the official approved dosing 2. Most international guidelines (WHO, European) still recommend the standard 3-day course 3. The 5-day extension is specifically a CDC recommendation for the United States based on surveillance of treatment failures in returned travelers.
Critical Administration Requirements
Regardless of duration, AL must be taken with fatty food or drink to ensure adequate absorption 3. Poor adherence or malabsorption can mimic treatment failure. Patients should be counseled to resume eating as soon as tolerated, as this significantly improves lumefantrine absorption 2.
Geographic Considerations
For infections acquired in Southeast Asia (Greater Mekong subregion) where confirmed artemisinin resistance exists, consider alternative agents like atovaquone-proguanil rather than any AL regimen 3.
Monitoring for Post-Treatment Complications
Post-artemisinin delayed hemolysis (PADH) occurs in up to 37% of patients by day 14 after ACT treatment when strict laboratory definitions are used 3. All patients treated with AL should have follow-up hemoglobin monitoring at 1-2 weeks post-treatment, regardless of regimen duration.
Alternative Agents
If AL is contraindicated (QT prolongation risk) or treatment failure occurs, second-line options include:
The evidence supporting the 5-day AL regimen is based on pharmacokinetic data, treatment failure surveillance, and safety assessments rather than head-to-head randomized trials 1. However, given the concerning trend of late recrudescences and the safety profile of extended dosing, the CDC's recommendation to extend to 5 days represents a prudent response to evolving treatment failure patterns in returned travelers.